{"id":"nicotinamide","rwe":[],"_fda":{"id":"e03ca6f2-c438-4b0a-9c19-db16e88697ac","set_id":"05813526-41d0-4451-8543-f4288ba7eb95","openfda":{"nui":["N0000185508","N0000175629","N0000184306","M0000728","M0005152","N0000175831","N0000008595","N0000008924","N0000175830"],"unii":["0R0008Q3JB","789U1901C5","935E97BOY8","25X51I8RD4","H6241UJ22B","J41CSQ7QDS"],"route":["ORAL"],"spl_id":["e03ca6f2-c438-4b0a-9c19-db16e88697ac"],"brand_name":["Nicotinamide"],"spl_set_id":["05813526-41d0-4451-8543-f4288ba7eb95"],"package_ndc":["42192-374-60"],"product_ndc":["42192-374"],"generic_name":["NICOTINAMIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Allergens [CS]","Copper [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]","Decreased Embryonic Implantation [PE]","Decreased Sperm Motility [PE]","Inhibit Ovum Fertilization [PE]"],"substance_name":["CHROMIUM","COPPER","FOLIC ACID","NIACINAMIDE","SELENIUM","ZINC"],"pharm_class_epc":["Standardized Chemical Allergen [EPC]","Copper-containing Intrauterine Device [EPC]"],"manufacturer_name":["Acella Pharmaceuticals, LLC"],"is_original_packager":[true]},"version":"5","warnings":["THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. WARNINGS: If you are pregnant, nursing, or taking medication, consult your doctor before use. Use only under the advice and supervision of a physician if you have a history of jaundice, liver disease or diabetes. Abnormal liver function tests have been reported in persons taking daily doses of 500 mg or more of niacinamide. Folate intake should not exceed 250% of the Daily Value (1,000 mcg). PREGNANCY & NURSING MOTHERS: Nicotinamide Tablets is not indicated for use as a prenatal/postnatal multivitamin for lactating and nonlactating mothers. Physicians and medical practitioners should administer Nicotinamide Tablets with caution to patients who are pregnant, lactating and/or taking medication. ADVERSE REACTIONS: Allergic sensitization has been reported rarely following oral and parental administration of Folate."],"precautions":["PRECAUTIONS: Large doses of Nicotinamide Tablets should be administered with caution in patients with a history of jaundice, liver disease, or diabetes. Patients with chronic liver failure and/or renal failure should exercise extreme caution in taking prescribed supplements containing copper. Folic acid alone is improper treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid especially in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission may occur while neurological manifestations remain progressive"],"effective_time":"20250213","warnings_table":["
WARNINGS: If you are pregnant, nursing, or taking medication, consult your doctor before use. Use only under the advice and supervision of a physician if you have a history of jaundice, liver disease or diabetes. Abnormal liver function tests have been reported in persons taking daily doses of 500 mg or more of niacinamide. Folate intake should not exceed 250% of the Daily Value (1,000 mcg).
"],"statement_of_identity":["RX Only Dietary Supplement DESCRIPTION: Nicotinamide Tablets is a prescription dietary supplement for oral administration, specifically formulated for the dietary management of patients with unique nutritional needs who require increased levels of one or more of the ingredients in this product. Each white-colored, oval-shaped tablet is debossed with “342” on one side and blank on the other. Supplement Facts Serving Size: 1 Tablet Amount per serving: % Daily Value Nicotinamide 750 mg 4700% Zinc (as Zinc Bisglycinate Chelate)* 27 mg 245% Folate (as (6S)-N5-Methyl- tetrahydrofolic Acid Calcium Salt 850 mcg DFE 210% (Equivalent to 500 mcg Folic Acid, USP)) Copper (as Cupric Oxide) 2 mg 220% Selenium (Selenium Amino Acid Chelate) 50 mcg 90% Chromium (Chromium Amino Acid Chelate) 100 mcg 290% OTHER INGREDIENTS: Crosscarmellose Sodium, Magnesium Stearate, Methocel K, Microcrystalline Cellulose, Silicon Dioxide and Stearic Acid. Coating contains: Hydroxypropyl Methylcellulose, Titanium Dioxide and Triacetin. INDICATIONS: Nicotinamide Tablets is indicated for use as a dietary supplement for patients who are deficient in, or who are at risk for deficiency in one or more of the ingredients in this product. CONTRAINDICATIONS: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION: Take 1-2 tablets daily, as a dietary supplement, as directed by your physician. HOW SUPPLIED: Nicotinamide Tablets are white-colored, oval-shaped tablets debossed on one side with “342”, and are supplied in bottles of 60 tablets (42192-374-60). The listed product number is not a National Drug Code. Instead, Acella has assigned a product code formatted according to standard industry practice in order to comply with the formatting requirements of pharmacy and healthcare insurance computer systems. STORAGE: Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F). [See USP Controlled Room Temperature.] MANUFACTURED FOR: Acella Pharmaceuticals, LLC Alpharetta, GA 30005 1-800-541-4802 L-0289 Rev 0321-01 *Subject to one or more claims of U.S. Patent Nos. 7,582,418, 7,838,042 and 8,425,956."],"spl_product_data_elements":["Nicotinamide Nicotinamide NIACINAMIDE NIACINAMIDE ZINC ZINC FOLIC ACID FOLIC ACID COPPER COPPER SELENIUM SELENIUM CHROMIUM CHROMIUM CROSCARMELLOSE SODIUM MAGNESIUM STEARATE HYPROMELLOSE 2208 (100 MPA.S) MICROCRYSTALLINE CELLULOSE SILICON DIOXIDE STEARIC ACID HYPROMELLOSE, UNSPECIFIED TITANIUM DIOXIDE TRIACETIN 342"],"statement_of_identity_table":["
Supplement Facts
Serving Size: 1 Tablet
Amount per serving: % Daily Value
Nicotinamide750 mg4700%
Zinc (as Zinc Bisglycinate Chelate)*27 mg245%
Folate (as (6S)-N5-Methyl- tetrahydrofolic Acid Calcium Salt850 mcg DFE210%
(Equivalent to 500 mcg Folic Acid, USP))
Copper (as Cupric Oxide)2 mg220%
Selenium (Selenium Amino Acid Chelate)50 mcg90%
Chromium (Chromium Amino Acid Chelate)100 mcg290%
"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL C:\\Users\\admin\\Desktop\\nicotinamide\\nicotinamide-label.jpg"]},"tags":[{"label":"nicotinamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"NAD-dependent protein deacetylase sirtuin-2","category":"target"},{"label":"SIRT2","category":"gene"},{"label":"SIRT3","category":"gene"},{"label":"SARM1","category":"gene"},{"label":"A11HA01","category":"atc"},{"label":"Topical","category":"route"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Concentrate","category":"form"},{"label":"Cream","category":"form"},{"label":"Active","category":"status"},{"label":"Acne vulgaris","category":"indication"},{"label":"Niacin deficiency","category":"indication"},{"label":"Pellagra","category":"indication"},{"label":"Hospira","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Micronutrients","category":"pharmacology"},{"label":"Vitamin B Complex","category":"pharmacology"},{"label":"Vitamins","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"696 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"616 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"600 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"584 reports"},{"date":"","signal":"MALAISE","source":"FDA FAERS","actionTaken":"427 reports"},{"date":"","signal":"INFUSION RELATED REACTION","source":"FDA FAERS","actionTaken":"421 reports"},{"date":"","signal":"DYSPEPSIA","source":"FDA FAERS","actionTaken":"397 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"390 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"381 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"363 reports"}],"commonSideEffects":[{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Erythema","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritis","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Agitation","drugRate":"","severity":"common","organSystem":""},{"effect":"Anxiety","drugRate":"","severity":"common","organSystem":""},{"effect":"Diplopia","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute coronary syndrome","Acute tuberculosis","Anemia due to enzyme deficiency","Arterial hemorrhage","Blood coagulation disorder","Bronchitis","Dermatitis herpetiformis","Diabetes mellitus","Disease of liver","Goiter","Gout","Hashimoto thyroiditis","Hb SS disease","Hemochromatosis","Hemophilia","Hyperkalemia","Hypocomplementemic urticarial vasculitis","Kidney disease","Low blood pressure","Peptic ulcer","Pregnancy, function","Primary hyperoxaluria","Rhabdomyolysis"],"seriousAdverseEvents":[{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Anaphylactoid reactions","drugRate":"","severity":"serious"},{"effect":"Shortness of breath","drugRate":"","severity":"serious"},{"effect":"Wheezing","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Allergic reactions to thiamine","drugRate":"","severity":"serious"},{"effect":"Hypervitaminosis A","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["Enduramide","Niacin (Vitamin B3)","niacinamide","Decitabine","Tetrahydrouridine"],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Nicotinamide","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:16:48.827700+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:16:54.055626+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nicotinamide","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:16:54.431288+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:16:47.360592+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:16:47.360616+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:16:47.360622+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:16:56.315411+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1140/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:55.531558+00:00"}},"allNames":"infuvite adult","offLabel":[],"synonyms":["niacinamide","nicotinamide","3-pyridinecarboxamide"],"timeline":[{"date":"1953-02-20","type":"positive","source":"DrugCentral","milestone":"FDA approval (Hospira)"}],"approvals":[{"date":"1953-02-20","orphan":false,"company":"HOSPIRA","regulator":"FDA"}],"brandName":"Infuvite Adult","ecosystem":[{"indication":"Acne vulgaris","otherDrugs":[{"name":"adapalene","slug":"adapalene","company":"Galderma Labs Lp"},{"name":"ammonia","slug":"ammonia","company":""},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"azelaic acid","slug":"azelaic-acid","company":"Allergan"}],"globalPrevalence":null},{"indication":"Niacin deficiency","otherDrugs":[{"name":"inositol","slug":"inositol","company":""},{"name":"inositol nicotinate","slug":"inositol-nicotinate","company":""},{"name":"nicotine","slug":"nicotine","company":"Sanofi Aventis Us"}],"globalPrevalence":null},{"indication":"Pellagra","otherDrugs":[{"name":"inositol","slug":"inositol","company":""},{"name":"inositol nicotinate","slug":"inositol-nicotinate","company":""},{"name":"nicotine","slug":"nicotine","company":"Sanofi Aventis Us"}],"globalPrevalence":null}],"mechanism":{"target":"NAD-dependent protein deacetylase sirtuin-2","novelty":"First-in-class","targets":[{"gene":"SIRT2","source":"DrugCentral","target":"NAD-dependent protein deacetylase sirtuin-2","protein":"NAD-dependent protein deacetylase sirtuin-2"},{"gene":"SIRT3","source":"DrugCentral","target":"NAD-dependent deacetylase sirtuin 3","protein":"NAD-dependent protein deacetylase sirtuin-3, mitochondrial"},{"gene":"SARM1","source":"DrugCentral","target":"Sterile alpha and TIR motif-containing protein 1","protein":"Sterile alpha and TIR motif-containing protein 1"},{"gene":"SIRT5","source":"DrugCentral","target":"NAD-dependent protein deacylase sirtuin-5, mitochondrial","protein":"NAD-dependent protein deacylase sirtuin-5, mitochondrial"},{"gene":"SIRT1","source":"DrugCentral","target":"NAD-dependent protein deacetylase sirtuin-1","protein":"NAD-dependent protein deacetylase sirtuin-1"},{"gene":"HCAR2","source":"DrugCentral","target":"Hydroxycarboxylic acid receptor 2","protein":"Hydroxycarboxylic acid receptor 2"},{"gene":"HCAR3","source":"DrugCentral","target":"Hydroxycarboxylic acid receptor 3","protein":"Hydroxycarboxylic acid receptor 3"},{"gene":"NNMT","source":"DrugCentral","target":"Nicotinamide N-methyltransferase","protein":"Nicotinamide N-methyltransferase"},{"gene":"QPRT","source":"DrugCentral","target":"Nicotinate-nucleotide pyrophosphorylase [carboxylating]","protein":"Nicotinate-nucleotide pyrophosphorylase [carboxylating]"}],"modality":"Small Molecule","drugClass":"Standardized Chemical Allergen [EPC]","explanation":"","oneSentence":"","technicalDetail":"Infuvite Adult targets NAD-dependent protein deacetylase sirtuin-2, a key enzyme involved in cellular energy metabolism and epigenetic regulation."},"commercial":{"launchDate":"1953","_launchSource":"DrugCentral (FDA 1953-02-20, HOSPIRA)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1906","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Nicotinamide","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nicotinamide","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:57:06.580285","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:16:57.289918+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"pyridoxine","drugSlug":"pyridoxine","fdaApproval":"1993-12-29","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"Vitamin E","drugSlug":"vitamin-e","fdaApproval":"1953-02-20","relationship":"same-class"},{"drugName":"riboflavin","drugSlug":"riboflavin","fdaApproval":"1953-02-20","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"biotin","drugSlug":"biotin","fdaApproval":"1953-02-20","relationship":"same-class"},{"drugName":"pyridoxal phosphate","drugSlug":"pyridoxal-phosphate","fdaApproval":"","relationship":"same-class"},{"drugName":"inositol","drugSlug":"inositol","fdaApproval":"","relationship":"same-class"},{"drugName":"tocofersolan","drugSlug":"tocofersolan","fdaApproval":"","relationship":"same-class"},{"drugName":"dexpanthenol","drugSlug":"dexpanthenol","fdaApproval":"1953-02-20","relationship":"same-class"},{"drugName":"calcium pantothenate","drugSlug":"calcium-pantothenate","fdaApproval":"1993-12-29","relationship":"same-class"},{"drugName":"pantethine","drugSlug":"pantethine","fdaApproval":"","relationship":"same-class"}],"genericName":"nicotinamide","indications":{"approved":[{"name":"Acne vulgaris","source":"DrugCentral","snomedId":88616000,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Niacin deficiency","source":"DrugCentral","snomedId":418279001,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Pellagra","source":"DrugCentral","snomedId":418186002,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[{"name":"Methemoglobinemia","source":"DrugCentral","drugName":"Nicotinamide"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pyridoxine","brandName":"pyridoxine","genericName":"pyridoxine","approvalYear":"1993","relationship":"same-class"},{"drugId":"vitamin-e","brandName":"Vitamin E","genericName":"Vitamin E","approvalYear":"1953","relationship":"same-class"},{"drugId":"riboflavin","brandName":"riboflavin","genericName":"riboflavin","approvalYear":"1953","relationship":"same-class"},{"drugId":"biotin","brandName":"biotin","genericName":"biotin","approvalYear":"1953","relationship":"same-class"},{"drugId":"pyridoxal-phosphate","brandName":"pyridoxal phosphate","genericName":"pyridoxal phosphate","approvalYear":"","relationship":"same-class"},{"drugId":"inositol","brandName":"inositol","genericName":"inositol","approvalYear":"","relationship":"same-class"},{"drugId":"tocofersolan","brandName":"tocofersolan","genericName":"tocofersolan","approvalYear":"","relationship":"same-class"},{"drugId":"dexpanthenol","brandName":"dexpanthenol","genericName":"dexpanthenol","approvalYear":"1953","relationship":"same-class"},{"drugId":"calcium-pantothenate","brandName":"calcium pantothenate","genericName":"calcium pantothenate","approvalYear":"1993","relationship":"same-class"},{"drugId":"pantethine","brandName":"pantethine","genericName":"pantethine","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01303341","phase":"PHASE1","title":"Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-18","conditions":["Advanced Malignant Solid Neoplasm","Recurrent Melanoma","Refractory Malignant Solid Neoplasm","Stage III Cutaneous Melanoma AJCC v7","Stage IIIA Cutaneous Melanoma AJCC v7","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7"],"enrollment":35,"completionDate":"2026-09-17"},{"nctId":"NCT06044935","phase":"NA","title":"Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2024-01-08","conditions":["Overweight","Obesity"],"enrollment":100,"completionDate":"2028-01-31"},{"nctId":"NCT01861314","phase":"PHASE1","title":"Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-03","conditions":["Acute Myeloid Leukemia","Acute Myeloid Leukemia Post Cytotoxic Therapy","Recurrent Adult Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia"],"enrollment":15,"completionDate":"2027-03-19"},{"nctId":"NCT04430517","phase":"EARLY_PHASE1","title":"Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mclean Hospital","startDate":"2022-03-02","conditions":["Mild Cognitive Impairment","Mild Alzheimer Disease"],"enrollment":50,"completionDate":"2026-05-15"},{"nctId":"NCT02298348","phase":"PHASE1","title":"Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2015-10-08","conditions":["Neuroblastoma"],"enrollment":18,"completionDate":"2026-12"},{"nctId":"NCT06587945","phase":"PHASE4","title":"Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment","status":"RECRUITING","sponsor":"Center for Eye Research Australia","startDate":"2025-09-19","conditions":["Retinal Detachment"],"enrollment":144,"completionDate":"2028-03-30"},{"nctId":"NCT07463651","phase":"PHASE3","title":"MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-05-01","conditions":["Acute Myeloid Leukemia (AML)","FLT3-ITD Mutation","Allogeneic Hematopoietic Cell Transplantation (HCT)","Maintenance Therapy","Gilteritinib","Sorafenib"],"enrollment":594,"completionDate":"2030-03-31"},{"nctId":"NCT03298451","phase":"PHASE3","title":"Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":["Hepatocellular Carcinoma"],"enrollment":1324,"completionDate":"2026-08-27"},{"nctId":"NCT05702398","phase":"EARLY_PHASE1","title":"Pilot Trial of Supplemental Vitamin A and Nicotinamide","status":"RECRUITING","sponsor":"Rhode Island Hospital","startDate":"2023-04-01","conditions":["Skin Cancer","Kidney Transplant Recipients"],"enrollment":30,"completionDate":"2028-03-01"},{"nctId":"NCT04614714","phase":"PHASE2,PHASE3","title":"Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-04-01","conditions":["Preterm Birth","Inadequate Milk Production"],"enrollment":40,"completionDate":"2027-12-31"},{"nctId":"NCT06309485","phase":"PHASE2","title":"Phase 2 Study of WGI-0301 for Advanced HCC","status":"RECRUITING","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","startDate":"2024-07-31","conditions":["Advanced Hepatocellular Carcinoma (HCC)"],"enrollment":60,"completionDate":"2027-03"},{"nctId":"NCT04720716","phase":"PHASE3","title":"A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-02-07","conditions":["Hepatocellular Carcinoma"],"enrollment":344,"completionDate":"2025-12-31"},{"nctId":"NCT07475208","phase":"NA","title":"NR and Exercise for Blood Pressure","status":"NOT_YET_RECRUITING","sponsor":"ZHANG Jiaqi","startDate":"2026-04","conditions":["Hypertension (HTN)"],"enrollment":112,"completionDate":"2027-12"},{"nctId":"NCT07344636","phase":"NA","title":"Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training","status":"RECRUITING","sponsor":"ZHANG Jiaqi","startDate":"2026-01-06","conditions":["Health Adult Subjects"],"enrollment":16,"completionDate":"2027-07"},{"nctId":"NCT06345443","phase":"NA","title":"NRM on Vascular Perfusion in Healthy Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2024-11-25","conditions":["Vascular Stiffness"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT07477275","phase":"NA","title":"Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation","status":"ACTIVE_NOT_RECRUITING","sponsor":"USMARI Research & Innovation Centre","startDate":"2024-12-01","conditions":["Dark Spots"],"enrollment":68,"completionDate":"2026-04-30"},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":["Healthspan Improvement","Aging","Longevity"],"enrollment":30,"completionDate":"2026-04"},{"nctId":"NCT05468359","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-11-07","conditions":["Refractory Solid Tumor","Hepatocellular Carcinoma","Malignant Solid Tumor","Pediatric Cancer","Pediatric Solid Tumor","Fibrolamellar Carcinoma"],"enrollment":64,"completionDate":"2037-06"},{"nctId":"NCT06579209","phase":"NA","title":"NAD+ Oral Supplement Pilot Intervention in Adult Females","status":"COMPLETED","sponsor":"University of Rhode Island","startDate":"2024-12-01","conditions":["Cognitive Change","Inflammation","Neurodegenerative Diseases"],"enrollment":53,"completionDate":"2026-02-20"},{"nctId":"NCT06534944","phase":"PHASE1,PHASE2","title":"NAD Supplementation and Vascular Health in PAD","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2023-02-27","conditions":["Peripheral Artery Disease"],"enrollment":8,"completionDate":"2024-12-30"},{"nctId":"NCT06787430","phase":"PHASE4","title":"Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2026-03-01","conditions":["STEMI - ST-segment Elevation Myocardial Infarction"],"enrollment":170,"completionDate":"2027-12-31"},{"nctId":"NCT07468175","phase":"NA","title":"A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation","status":"COMPLETED","sponsor":"Revision Skincare","startDate":"2024-10-21","conditions":["Hyperpigmentation","Dark Spots"],"enrollment":48,"completionDate":"2025-03-27"},{"nctId":"NCT04192136","phase":"NA","title":"NAD+ and Exercise in FA","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-09-03","conditions":["Friedreich Ataxia 1"],"enrollment":75,"completionDate":"2025-10-31"},{"nctId":"NCT04571008","phase":"NA","title":"Effect of NMN Supplementation on Organ System Biology","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-10-01","conditions":["Glucose Metabolism Disorders"],"enrollment":56,"completionDate":"2025-03-04"},{"nctId":"NCT00939627","phase":"PHASE2","title":"Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07","conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"enrollment":55,"completionDate":"2014-01"},{"nctId":"NCT05986123","phase":"NA","title":"Safety and Efficacy of Topical Cream for Post-inflammatory Hyperpigmentation Skin Among Malaysians","status":"COMPLETED","sponsor":"USMARI Research & Innovation Centre","startDate":"2023-11-01","conditions":["Healthy"],"enrollment":25,"completionDate":"2026-01-30"},{"nctId":"NCT07451496","phase":"NA","title":"PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-09-29","conditions":["Ageing"],"enrollment":20,"completionDate":"2026-06-30"},{"nctId":"NCT06760533","phase":"EARLY_PHASE1","title":"Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2026-08","conditions":["IBS - Irritable Bowel Syndrome"],"enrollment":10,"completionDate":"2026-12"},{"nctId":"NCT06582706","phase":"PHASE1,PHASE2","title":"Nicotinic Acid for the Treatment of Alzheimer's Disease","status":"RECRUITING","sponsor":"Indiana University","startDate":"2024-12-19","conditions":["Alzheimer Disease"],"enrollment":30,"completionDate":"2026-12"},{"nctId":"NCT06200155","phase":"PHASE2","title":"Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-04-16","conditions":["Depression, Anxiety","Psilocybin-Assisted Psychotherapy","Advanced Cancer"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT02185560","phase":"","title":"Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2014-06-27","conditions":["Thyroid Carcinoma"],"enrollment":453,"completionDate":"2026-09-30"},{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":["Metastatic Renal Cell Carcinoma (mRCC)"],"enrollment":554,"completionDate":"2022-09-30"},{"nctId":"NCT07428889","phase":"NA","title":"Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement","status":"RECRUITING","sponsor":"Shaklee Corporation","startDate":"2026-02","conditions":["Healthy Adult"],"enrollment":34,"completionDate":"2026-06"},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":["Desmoplastic Small Round Cell Tumor","Ewing Sarcoma of Bone or Soft Tissue","Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor"],"enrollment":24,"completionDate":"2026-07"},{"nctId":"NCT07144527","phase":"NA","title":"Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults","status":"RECRUITING","sponsor":"Scott Silveira","startDate":"2026-02-21","conditions":["Aging","Frailty","Exercise Tolerance","Healthy Male and Female Subjects"],"enrollment":40,"completionDate":"2027-01-01"},{"nctId":"NCT02559778","phase":"PHASE2","title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2015-09","conditions":["Neuroblastoma"],"enrollment":500,"completionDate":"2035-09"},{"nctId":"NCT07245979","phase":"NA","title":"Supplementation With Sirtuin Activators in Women With Increased Body Weight","status":"RECRUITING","sponsor":"Poznan University of Life Sciences","startDate":"2025-10-08","conditions":["Obesity & Overweight"],"enrollment":120,"completionDate":"2027-03-01"},{"nctId":"NCT07286318","phase":"EARLY_PHASE1","title":"A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients","status":"NOT_YET_RECRUITING","sponsor":"Marissa Lobl","startDate":"2026-03-01","conditions":["Skin Cancer","Cutaneous Squamous Cell Carcinoma (CSCC)","Actinic Keratosis (AK)","Organ Transplant Recipient"],"enrollment":20,"completionDate":"2027-06-30"},{"nctId":"NCT04039607","phase":"PHASE3","title":"A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-09-30","conditions":["Hepatocellular Carcinoma"],"enrollment":732,"completionDate":"2026-11-09"},{"nctId":"NCT07013591","phase":"PHASE2","title":"Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-03-31","conditions":["Coronary Artery Bypass Graft"],"enrollment":90,"completionDate":"2029-01-01"},{"nctId":"NCT05669339","phase":"PHASE2","title":"AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-12-02","conditions":["Hepatocellular Carcinoma"],"enrollment":12,"completionDate":"2026-04"},{"nctId":"NCT07416786","phase":"NA","title":"Validation of NAD+ Measurements for Human Clinical Studies","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-04-01","conditions":["Healthy Adults"],"enrollment":48,"completionDate":"2028-07-31"},{"nctId":"NCT06627868","phase":"NA","title":"Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue","status":"RECRUITING","sponsor":"University of Turku","startDate":"2024-11-20","conditions":["Obesity, Abdominal"],"enrollment":68,"completionDate":"2027-08-31"},{"nctId":"NCT04332341","phase":"EARLY_PHASE1","title":"Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2020-05-19","conditions":["Allogeneic Hematopoietic Cell Transplantation"],"enrollment":20,"completionDate":"2026-09"},{"nctId":"NCT06032923","phase":"PHASE1,PHASE2","title":"Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2024-03-13","conditions":["Systemic Lupus Erythematosus (Sle)"],"enrollment":78,"completionDate":"2028-08-01"},{"nctId":"NCT07414212","phase":"PHASE1,PHASE2","title":"Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)","status":"RECRUITING","sponsor":"Biogipuzkoa Health Research Institute","startDate":"2025-11-25","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":90,"completionDate":"2027-11-25"},{"nctId":"NCT04770896","phase":"PHASE3","title":"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-04-26","conditions":["Unresectable Hepatocellular Carcinoma"],"enrollment":557,"completionDate":"2026-06-30"},{"nctId":"NCT06227221","phase":"PHASE2","title":"Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-02","conditions":["Type 1 Diabetes"],"enrollment":10,"completionDate":"2029-06"},{"nctId":"NCT05092945","phase":"NA","title":"Brown Adipose Tissue Metabolism in Type 2 Diabetes","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2021-05-18","conditions":["Type 2 Diabetes"],"enrollment":6,"completionDate":"2025-08-18"},{"nctId":"NCT02143726","phase":"PHASE2","title":"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-10-09","conditions":["Refractory Hurthle Cell Thyroid Cancer"],"enrollment":35,"completionDate":"2028-08-06"},{"nctId":"NCT05934409","phase":"NA","title":"Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2023-11-01","conditions":["Diabetes Mellitus Type 2"],"enrollment":40,"completionDate":"2028-05-01"},{"nctId":"NCT06843148","phase":"NA","title":"Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2026-04","conditions":["Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Liver Fibrosis/NASH","Non-Alcoholic Steato-Hepatitis (NASH)"],"enrollment":36,"completionDate":"2030-07"},{"nctId":"NCT01903694","phase":"PHASE3","title":"Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2010-03","conditions":["Child-Pugh A Hepatocellular Carcinoma"],"enrollment":474,"completionDate":""},{"nctId":"NCT01275300","phase":"NA","title":"Biosynthesis of PGD2 in Vivo","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-07","conditions":["Hyperlipidemia"],"enrollment":9,"completionDate":"2012-01"},{"nctId":"NCT00989469","phase":"PHASE1,PHASE2","title":"Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2009-02","conditions":["Metastatic Colorectal Cancer"],"enrollment":64,"completionDate":"2012-02"},{"nctId":"NCT03211416","phase":"PHASE1,PHASE2","title":"Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-12-07","conditions":["Advanced Adult Hepatocellular Carcinoma","Child-Pugh Class A","Stage III Hepatocellular Carcinoma","Stage IIIA Hepatocellular Carcinoma","Stage IIIB Hepatocellular Carcinoma","Stage IIIC Hepatocellular Carcinoma","Stage IV Hepatocellular Carcinoma","Stage IVA Hepatocellular Carcinoma","Stage IVB Hepatocellular Carcinoma"],"enrollment":37,"completionDate":"2025-08-15"},{"nctId":"NCT06983730","phase":"EARLY_PHASE1","title":"The Kidney's Response to Exercise in Heat, and the Impact of Vitamin B3 on This Response","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2026-01-26","conditions":["Heat Strain","Healthy Volunteer Study","Kidney Dysfunction"],"enrollment":28,"completionDate":"2028-06"},{"nctId":"NCT01715441","phase":"PHASE2","title":"Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2012-09","conditions":["Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors"],"enrollment":173,"completionDate":"2015-09"},{"nctId":"NCT07380438","phase":"NA","title":"A Clinical Study to Evaluate the Efficacy of a Nutritional Supplement to Improve Carotenoid Content as Measured by a Non-invasive Hyperspectral Absorption Device","status":"COMPLETED","sponsor":"Pharmanex","startDate":"2025-10-20","conditions":["Nutrition Assessment"],"enrollment":84,"completionDate":"2026-01-08"},{"nctId":"NCT06861088","phase":"PHASE3","title":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Quercis Pharma AG","startDate":"2025-12-19","conditions":["Venous Thromboembolism","Metastatic Pancreatic Cancer","Locally Advanced Pancreatic Adenocarcinoma"],"enrollment":480,"completionDate":"2029-10-31"},{"nctId":"NCT06018467","phase":"PHASE2","title":"Senolytics to Improve Osteoporosis Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Odense University Hospital","startDate":"2023-09-06","conditions":["Osteopenia, Osteoporosis","Age-related Bone Loss"],"enrollment":120,"completionDate":"2026-04-30"},{"nctId":"NCT01730937","phase":"PHASE3","title":"Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2013-04","conditions":["Adult Primary Hepatocellular Carcinoma","Advanced Adult Primary Liver Cancer","Recurrent Adult Primary Liver Cancer"],"enrollment":193,"completionDate":"2025-09-04"},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":206,"completionDate":"2027-06"},{"nctId":"NCT04914845","phase":"PHASE1","title":"KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-08-27","conditions":["Acute Myeloid Leukemia","Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory"],"enrollment":16,"completionDate":"2025-10-22"},{"nctId":"NCT05590468","phase":"PHASE2","title":"A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ralitza Gavrilova","startDate":"2023-05-26","conditions":["Mitochondrial Myopathy"],"enrollment":34,"completionDate":"2026-11"},{"nctId":"NCT05878119","phase":"PHASE2","title":"Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program","status":"COMPLETED","sponsor":"Metro International Biotech, LLC","startDate":"2023-10-25","conditions":["Healthy"],"enrollment":124,"completionDate":"2025-08-04"},{"nctId":"NCT00826540","phase":"PHASE2","title":"Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":["Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer","Stage IV Rectal Cancer"],"enrollment":83,"completionDate":"2014-02"},{"nctId":"NCT05561738","phase":"NA","title":"Nicotinamide Riboside in Ulcerative Colitis","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2024-02-28","conditions":["Ulcerative Colitis"],"enrollment":40,"completionDate":"2026-06-30"},{"nctId":"NCT07350538","phase":"NA","title":"The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Roehampton","startDate":"2025-12-10","conditions":["Healthy Subjects"],"enrollment":20,"completionDate":"2026-06-15"},{"nctId":"NCT07341217","phase":"NA","title":"Chemo Brain Prehab Project","status":"NOT_YET_RECRUITING","sponsor":"Dr. Chris Gaffney","startDate":"2026-01-30","conditions":["Colorectal Cancer","Older Adults (60 - 85 Years Old)","Physically Inactive","Chemotherapy"],"enrollment":86,"completionDate":"2027-09-16"},{"nctId":"NCT07271316","phase":"PHASE2","title":"Alii Supplement Study","status":"RECRUITING","sponsor":"Texas Christian University","startDate":"2026-01-12","conditions":["Nutrient Deficiency","Happiness","Digestive Health","Vulnerability to Disease","Mood Swings","Energy"],"enrollment":68,"completionDate":"2026-04-29"},{"nctId":"NCT07337486","phase":"NA","title":"\"Evaluation of a Non-Pharmacological Skin Care Intervention for the Prevention and Treatment of Skin Toxicities Caused by Immunotherapy in Cancer Patients\"","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2022-05-30","conditions":["Skin Toxicity in Patients on Checkpoint Inhibitors"],"enrollment":130,"completionDate":"2024-10-30"},{"nctId":"NCT04562831","phase":"NA","title":"The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2020-10-07","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":380,"completionDate":"2026-10-31"},{"nctId":"NCT05224336","phase":"PHASE1","title":"Psilocybin-assisted Therapy for Phantom Limb Pain","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2022-10-03","conditions":["Phantom Limb Pain"],"enrollment":10,"completionDate":"2024-03-07"},{"nctId":"NCT03685253","phase":"PHASE1,PHASE2","title":"Nicotinamide Riboside for Diabetic Neuropathy","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2019-01-24","conditions":["Diabetic Neuropathy Peripheral"],"enrollment":10,"completionDate":"2022-05-01"},{"nctId":"NCT04677049","phase":"PHASE1,PHASE2","title":"Study of Niacin in Glioblastoma","status":"SUSPENDED","sponsor":"AHS Cancer Control Alberta","startDate":"2021-03-18","conditions":["Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype"],"enrollment":59,"completionDate":"2026-12-31"},{"nctId":"NCT05117957","phase":"PHASE2","title":"Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study","status":"COMPLETED","sponsor":"Bo Hyun Kim","startDate":"2022-03-08","conditions":["Advanced Hepatocellular Carcinoma"],"enrollment":50,"completionDate":"2025-12-18"},{"nctId":"NCT07306364","phase":"PHASE2","title":"Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-06","conditions":["Chronic Low Back Pain (CLBP)","Physical Therapy","Psilocybin"],"enrollment":45,"completionDate":"2029-06"},{"nctId":"NCT07022938","phase":"PHASE4","title":"Nutritional Supplement for Treating Chemotherapy Induced Neuropathy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2021-11-01","conditions":["Cancer","Neuropathy","Chemotherapy Induced Pain Neuropathy","Chemotherapy-Induced Peripheral Neuropathy"],"enrollment":71,"completionDate":"2025-12-15"},{"nctId":"NCT01658878","phase":"PHASE1,PHASE2","title":"An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-10-30","conditions":["Hepatocellular Carcinoma"],"enrollment":657,"completionDate":"2024-11-12"},{"nctId":"NCT04784234","phase":"NA","title":"Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin","status":"TERMINATED","sponsor":"Wills Eye","startDate":"2021-02-01","conditions":["Primary Open Angle Glaucoma"],"enrollment":12,"completionDate":"2022-10-27"},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":["Childhood Hepatocellular Carcinoma","Childhood Malignant Liver Neoplasm","Fibrolamellar Carcinoma","Hepatoblastoma","Hepatocellular Malignant Neoplasm, Not Otherwise Specified"],"enrollment":537,"completionDate":"2026-12-31"},{"nctId":"NCT07296354","phase":"PHASE4","title":"Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy","status":"NOT_YET_RECRUITING","sponsor":"Egyptian International Pharmaceutical Industries Co","startDate":"2026-01-10","conditions":["Neuropathic Pain"],"enrollment":200,"completionDate":"2029-01-10"},{"nctId":"NCT07280637","phase":"NA","title":"Regenarative Treatment of Periocular Wrinkles With PDRN","status":"RECRUITING","sponsor":"University of Taubate","startDate":"2025-11-30","conditions":["Skin Wrinklings"],"enrollment":25,"completionDate":"2026-08-30"},{"nctId":"NCT07258667","phase":"PHASE1","title":"Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Angers","startDate":"2026-04","conditions":["Leber Hereditary Optic Neuropathy (LHON)","Leber's Hereditary Optic Neuropathy (LHON)","Mitochondrial Disease","Optic Nerve Disease"],"enrollment":13,"completionDate":"2028-04"},{"nctId":"NCT00494182","phase":"PHASE2","title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-25","conditions":["Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Squamous Cell Carcinoma of the Hypopharynx","Metastatic Squamous Cell Carcinoma of the Larynx","Metastatic Squamous Cell Carcinoma of the Oral Cavity","Metastatic Squamous Cell Carcinoma of the Oropharynx","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma"],"enrollment":48,"completionDate":"2026-12-31"},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":["Rhabdomyosarcoma"],"enrollment":115,"completionDate":"2030-06"},{"nctId":"NCT07284225","phase":"NA","title":"Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-12-20","conditions":["Healthy Volunteers"],"enrollment":20,"completionDate":"2026-12-30"},{"nctId":"NCT07286747","phase":"PHASE2","title":"Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Schleswig-Holstein","startDate":"2026-01-01","conditions":["Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)"],"enrollment":390,"completionDate":"2028-12-31"},{"nctId":"NCT04120766","phase":"PHASE2","title":"Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gregory Jicha, MD, PhD","startDate":"2021-12-01","conditions":["Dementia","Mild Cognitive Impairment"],"enrollment":64,"completionDate":"2026-11-30"},{"nctId":"NCT03247088","phase":"PHASE1,PHASE2","title":"Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-30","conditions":["Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":74,"completionDate":"2027-12-31"},{"nctId":"NCT07278492","phase":"PHASE1","title":"NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-04-01","conditions":["Down Syndrome (DS)"],"enrollment":24,"completionDate":"2028-06-30"},{"nctId":"NCT03755791","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2018-06-10","conditions":["Hepatocellular Carcinoma"],"enrollment":837,"completionDate":"2026-07-31"},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":["High-Risk Non-Muscle Invasive Bladder Cancer"],"enrollment":328,"completionDate":"2031-12-01"},{"nctId":"NCT05194397","phase":"PHASE2","title":"Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-02-23","conditions":["Lymphoblastic Leukemia","Cancer Survivors","Aplastic Anemia","Myelodysplastic Syndromes","Myeloid Leukemia"],"enrollment":80,"completionDate":"2026-06-30"},{"nctId":"NCT07264010","phase":"PHASE2,PHASE3","title":"Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-12-01","conditions":["Acute Myeloid Leukaemia (AML)","Measurable Residual Disease (MRD)"],"enrollment":87,"completionDate":"2028-12-30"},{"nctId":"NCT05398484","phase":"PHASE2,PHASE3","title":"Psilocybin Therapy in Advanced Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-05-24","conditions":["Advanced Cancer"],"enrollment":200,"completionDate":"2027-01-01"},{"nctId":"NCT04844528","phase":"PHASE2","title":"Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-02-25","conditions":["Chronic Lymphocytic Leukemia","Non-melanoma Skin Cancer (NMSC)"],"enrollment":86,"completionDate":"2028-08"},{"nctId":"NCT04004000","phase":"PHASE2","title":"Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension","status":"TERMINATED","sponsor":"Fulcrum Therapeutics","startDate":"2019-08-23","conditions":["Facioscapulohumeral Muscular Dystrophy 1"],"enrollment":14,"completionDate":"2024-10-31"},{"nctId":"NCT05617508","phase":"PHASE2","title":"N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2022-11-22","conditions":["Alzheimer Disease","Dementia"],"enrollment":80,"completionDate":"2025-06-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Concentrate, Cream","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Marnatal F"},{"form":"CAPSULE","route":"ORAL","productName":"Centratex"},{"form":"CAPSULE","route":"ORAL","productName":"Dexatran"},{"form":"CAPSULE","route":"ORAL","productName":"MYNEPHROCAPSDIALYSIS/STRESS Vitamin Supplement"},{"form":"CAPSULE","route":"ORAL","productName":"Prenara"},{"form":"CAPSULE","route":"ORAL","productName":"PureVit DualFe Plus"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"Se-Tan PLUS"},{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"Vitafol Fe Plus"},{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"Vitafol Ultra"},{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"Renal CapsDialysis/Stress Vitamin Supplement"},{"form":"CONCENTRATE","route":"TOPICAL","productName":"Anubis Barcelona"},{"form":"CONCENTRATE","route":"TOPICAL","productName":"Anubis Barcelona Regul OIl"},{"form":"CREAM","route":"TOPICAL","productName":"Anubis Barcelona Regul Oil"},{"form":"CREAM","route":"TOPICAL","productName":"COVERQUEEN All in one sun roll"},{"form":"CREAM","route":"TOPICAL","productName":"NATURAL SUN AQ TOTAL ANTI-AGING ESSENCE SUN"}]},"crossReferences":{"NUI":"N0000148162","MMSL":"4947","NDDF":"001055","UNII":"25X51I8RD4","VUID":"4020285","CHEBI":"CHEBI:17154","VANDF":"4017632","INN_ID":"404","RXNORM":"7405","UMLSCUI":"C0028027","chemblId":"CHEMBL1140","ChEMBL_ID":"CHEMBL1140","KEGG_DRUG":"D00036","DRUGBANK_ID":"DB02701","PDB_CHEM_ID":" NCA","PUBCHEM_CID":"936","SNOMEDCT_US":"173196005","MESH_DESCRIPTOR_UI":"D009536"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1953-","companyName":"Pfizer","relationship":"Original Developer"}],"publicationCount":29863,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A11HA01","allCodes":["A11HA01"]},"biosimilarFilings":[],"originalDeveloper":"Hospira","recentPublications":[],"combinationProducts":[{"brandName":"Adult Infuvite Multiple Vitamins","ingredients":"alpha-tocopherol acetate + ascorbic acid + biotin + colecalciferol + cyanocobalamin + dexpanthenol + folic acid + nicotinamide + phytomenadione + pyridoxine + thiamine + vitamin A palmitate"},{"brandName":"Adult Infuvite Multiple Vitamins for Infusion","ingredients":"alpha-tocopherol acetate + ascorbic acid + biotin + colecalciferol + cyanocobalamin + dexpanthenol + folic acid + nicotinamide + phytomenadione + pyridoxine + thiamine + vitamin A palmitate"},{"brandName":"Infuvite Adult Multiple Vitamins","ingredients":"alpha-tocopherol acetate + ascorbic acid + biotin + colecalciferol + cyanocobalamin + dexpanthenol + folic acid + nicotinamide + phytomenadione + pyridoxine + thiamine + vitamin A palmitate"},{"brandName":"PEDIATRIC INFUVITE MULTIPLE VITAMINS FOR INFUSION","ingredients":"alpha-tocopherol acetate + ascorbic acid + biotin + colecalciferol + cyanocobalamin + dexpanthenol + folic acid + nicotinamide + phytomenadione + pyridoxine + thiamine + vitamin A palmitate"},{"brandName":"Pediatric Infuvite Multiple Vitamins","ingredients":"alpha-tocopherol acetate + ascorbic acid + biotin + colecalciferol + cyanocobalamin + dexpanthenol + folic acid + nicotinamide + phytomenadione + pyridoxine + thiamine + vitamin A palmitate"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1953","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1953-02-20T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1953-02-20T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1953-02-20T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1953-02-20T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1953-02-20T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1953-02-20T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":20,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:16:57.289918+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}